Glenmark Pharmaceuticals Ltd.

₹2025.6

Glenmark Pharmaceuticals Ltd.

Add Alert
Add Watchlist

₹2025.6

₹2025.6

-27.0 (-1.32%) - 6 Aug 2025 04:28 PM

About Company

Glenmark Pharmaceuticals Limited is engaged in the development of new chemical entities (NCEs) and new biological entities (NBEs). Specialty Business: Drug Discovery: Glenmark’s ground-breaking drug discovery effort is primarily focused in the areas of inflammation [asthma/COPD, rheumatoid arthritis etc.], metabolic disorders [diabetes, obesity, etc.] and pain [neuropathic pain and inflammatory pain]. Specialty Business: Formulations Business: Glenmark’s formulations business is currently organized many regions - India, Latin America, Central Eastern Europe and Semi Regulated Markets of Africa/Asia/CIS. The formulations business focuses on therapeutic areas viz. dermatology, anti-infective, respiratory, cardiac, diabetes, gynecology, CNS, and oncology.

Market Cap. ₹ 57,163 Cr.
52 Week - High/Low ₹ 2,285/1,276
P/E Ratio 35.49
P/B Ratio 2.49
Enterprise Value ₹ 57,315 Cr.
ROE % 25.3
RSI Value 49.72
EMA 50 1889.25
EMA 200 1599.66
Market Cap. ₹ 57,163 Cr.
52 Week - High/Low ₹ 2,285/1,276
P/E Ratio 54.60
P/B Ratio 7.28
Enterprise Value ₹ 56,720 Cr.
ROE % -21.18
RSI Value 49.72
EMA 50 1889.25
EMA 200 1599.66

Valuation

Calculators

Peer Comparison

Industry - Pharmaceuticals & Drugs

* Please refer to the Standalone data if Consolidated financial data for the company is not available.

Shareholding Pattern Numbers in percentages

Insight market
Copyright © 2025 All rights reserved with INVESMATE INSIGHTS PRIVATE LIMITED | All logos and Trademarks registered with their respective owners.